Compare Cassava Sciences Inc (FLNA) vs Robinhood Markets, Inc. (HOOD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Robinhood Markets, Inc. — how do they compare? Cassava Sciences Inc trades at $1.1 (market cap $53.14M), while Robinhood Markets, Inc. trades at $105.74 (market cap $103.73B). The key difference: Robinhood Markets, Inc. is far larger — about 1952× Cassava Sciences Inc's market cap, and Robinhood Markets, Inc. is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | HOOD | |
|---|---|---|
Market Cap | $53.14M | $103.73B |
Sector | Health | Technology |
52-Week High | $4.64 | $152.46 |
52-Week Low | $1.09 | $65.16 |
Enterprise Value | -$33.43M | $104.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Robinhood (HOOD) trades at $110.23, down 2.84% on the day, with strong technical momentum indicated by bullish moving averages. The company reported robust 2025 results with $4.47B revenue and $1.88B net income, though Q1 2026 EPS slightly missed expectations. Recent news highlights expansion into financial services and positive analyst coverage, with 73% of analysts rating it a Buy.
The outlook remains positive given earnings growth and strategic initiatives, but risks include competitive pressures and market volatility. With a consensus price target of $112.07, near-term upside appears limited, yet long-term growth drivers like platform expansion support a constructive view for investors focused on financial technology growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Robinhood Markets, Inc.
Robinhood Markets, Inc. operates a financial services platform. The Company offers brokerage and cash management applications such as stocks, exchange-traded funds, options, and cryptocurrency. Robinhood Markets serves clients in the United States.
Read more on HOOD →
